In my opinion I don't think so. RGS is not in strong enough position to be spending its own cash on R&D. It's model is more about licensing out their products and having their licensing partners stump up the cash for trials/R&D. staff costs will also appear high at times like these. Without the staff trying to get the deals done there would be no RGS, and I doubt that the staff would choose to work for free.
In my opinion I don't think so. RGS is not in strong enough...
Add CMB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.772M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 1267251 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 746300 | 6 |
View Market Depth
| Last trade - 16.12pm 03/07/2024 (20 minute delay) ? |
| CMB (ASX) Chart |
Day chart unavailable